Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamibarotene Combo in RARA-positive AML (SELECT-AML-1)
NCT04905407Phase 2Terminated
- Sponsor
- Syros Pharmaceuticals
- Start
- Aug 2021
- Primary completion
- Aug 2024
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of tamibarotene in acute myeloid leukemia (AML) (4 arms), sponsored by Syros Pharmaceuticals. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events up to 3 years and Complete Remission/Complete Remission With Incomplete Hematologic Recovery Rate up to 3 years. Started Aug 2021; status: terminated.
02
Drugs
tamibarotene
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04905407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04905407.